“`html
Assessing the Benefit of Larotrectinib in Treating Infantile Fibrosarcoma
Background:
Patients with infantile fibrosarcoma (IFS) have responded well to larotrectinib, a type of treatment, but there is no data comparing its effectiveness to conventional chemotherapy.
Patients and Methods:
The study, called EPI VITRAKVI, looked at data from patients under 21 years old with IFS. It compared those treated with larotrectinib in a clinical trial with a control group treated with chemotherapy.
Results:
The study compared 93 patients and found that those treated with larotrectinib had a significantly lower likelihood of needing additional treatments compared to those treated with chemotherapy. The results were consistent across different analyses.
Conclusions:
The study concluded that treatment with larotrectinib reduced the need for additional therapies compared to standard chemotherapy in children with IFS, regardless of the treatment line.
“`
